Literature DB >> 19361352

Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification.

Hyun-Ju Cho1, Hyun-Jai Cho, Hyo-Soo Kim.   

Abstract

Osteopontin (OPN) was initially identified in osteoblasts as a mineralization-modulatory matrix protein. Recently, OPN has been studied as a multifunctional protein that is upregulated in a variety of acute and chronic inflammatory conditions, such as wound healing, fibrosis, autoimmune disease, and atherosclerosis. OPN is highly expressed at sites with atherosclerotic plaques, especially those associated with macrophages and foam cells. In the context of atherosclerosis, OPN is generally regarded as a proinflammatory and proatherogenic molecule. However, the role of OPN in vascular calcification (VC), which is closely related to chronic and active inflammation, is that of a negative regulator because it is an inhibitor of calcification and an active inducer of decalcification. OPN expression and its regulatory molecular mechanisms remain elusive during the process of VC. Therefore, further research with regard to the role of OPN in diseases associated with VC is needed to identify potential OPN-related therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19361352     DOI: 10.1007/s11883-009-0032-8

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  53 in total

Review 1.  The regulation and role of osteopontin in malignant transformation and cancer.

Authors:  Mohamed K El-Tanani; Frederick Charles Campbell; Vittal Kurisetty; Dachuan Jin; Mella McCann; Philip S Rudland
Journal:  Cytokine Growth Factor Rev       Date:  2006-11-17       Impact factor: 7.638

2.  Bone homeostasis.

Authors:  G A Rodan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

3.  Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin.

Authors:  T Wada; M D McKee; S Steitz; C M Giachelli
Journal:  Circ Res       Date:  1999-02-05       Impact factor: 17.367

Review 4.  Osteopontin: a versatile regulator of inflammation and biomineralization.

Authors:  C M Giachelli; S Steitz
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

Review 5.  Vitamin D and genomic stability.

Authors:  M Chatterjee
Journal:  Mutat Res       Date:  2001-04-18       Impact factor: 2.433

6.  Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence.

Authors:  A Oldberg; A Franzén; D Heinegård
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

Review 7.  Osteopontin as a target for cancer therapy.

Authors:  Nicholas I F Johnston; Vignesh Kumar Gunasekharan; Amod Ravindranath; Ciara O'Connell; Patrick G Johnston; Mohamed K El-Tanani
Journal:  Front Biosci       Date:  2008-05-01

8.  PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes.

Authors:  Takafumi Nakamachi; Takashi Nomiyama; Florence Gizard; Elizabeth B Heywood; Karrie L Jones; Yue Zhao; Lucia Fuentes; Kohzo Takebayashi; Yoshimasa Aso; Bart Staels; Toshihiko Inukai; Dennis Bruemmer
Journal:  Diabetes       Date:  2007-03-14       Impact factor: 9.461

9.  Plasma osteopontin levels are associated with the presence and extent of coronary artery disease.

Authors:  Reiko Ohmori; Yukihiko Momiyama; Hiroaki Taniguchi; Rie Takahashi; Masatoshi Kusuhara; Haruo Nakamura; Fumitaka Ohsuzu
Journal:  Atherosclerosis       Date:  2003-10       Impact factor: 5.162

10.  Altered vascular remodeling in osteopontin-deficient atherosclerotic mice.

Authors:  Asa Ström; Ahnders Franzén; Christel Wängnerud; Ann-Katrin Knutsson; Dick Heinegård; Anna Hultgårdh-Nilsson
Journal:  J Vasc Res       Date:  2004-06-21       Impact factor: 1.934

View more
  65 in total

1.  Gene-Lifestyle Interactions in Complex Diseases: Design and Description of the GLACIER and VIKING Studies.

Authors:  Azra Kurbasic; Alaitz Poveda; Yan Chen; Asa Agren; Elisabeth Engberg; Frank B Hu; Ingegerd Johansson; Ines Barroso; Anders Brändström; Göran Hallmans; Frida Renström; Paul W Franks
Journal:  Curr Nutr Rep       Date:  2014-12-01

2.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

Review 3.  Biomarkers of Calcific Aortic Valve Disease.

Authors:  Aeron Small; Daniel Kiss; Jay Giri; Saif Anwaruddin; Hasan Siddiqi; Marie Guerraty; Julio A Chirinos; Giovanni Ferrari; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-02-02       Impact factor: 8.311

4.  Enhanced tyrosine nitration of prostacyclin synthase is associated with increased inflammation in atherosclerotic carotid arteries from type 2 diabetic patients.

Authors:  Chaoyong He; Hyoung Chul Choi; Zhonglin Xie
Journal:  Am J Pathol       Date:  2010-03-26       Impact factor: 4.307

Review 5.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

Review 6.  In Search of the Ideal Valve: Optimizing Genetic Modifications to Prevent Bioprosthetic Degeneration.

Authors:  Benjamin Smood; Hidetaka Hara; David C Cleveland; David K C Cooper
Journal:  Ann Thorac Surg       Date:  2019-03-02       Impact factor: 4.330

7.  Validation of plasma biomarkers in degenerative calcific aortic stenosis.

Authors:  Giovanni Ferrari; Rachana Sainger; Erik Beckmann; Gianluca Keller; Pey-Jen Yu; Maria Cristina Monti; Aubrey C Galloway; Richard L Weiss; William Vernick; Juan B Grau
Journal:  J Surg Res       Date:  2010-05-06       Impact factor: 2.192

8.  Soluble levels of osteopontin in patients with Behcet's disease: association with disease activity and vascular involvement.

Authors:  Iman H Bassyouni; Mohammed M El-Wakd; Rasha H Bassyouni
Journal:  J Clin Immunol       Date:  2012-10-25       Impact factor: 8.317

9.  Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barré syndrome.

Authors:  Rong Kun Han; Yue Feng Cheng; Shan Shan Zhou; Hong Guo; Rui Dong He; Li Jun Chi; Li Ming Zhang
Journal:  J Clin Immunol       Date:  2013-11-12       Impact factor: 8.317

10.  Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.

Authors:  Justin D Blasberg; Harvey I Pass; Chandra M Goparaju; Raja M Flores; Suzie Lee; Jessica S Donington
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.